After decades of effort, malaria vaccines are reaching children at scale. Trials and rollouts showed meaningful reductions in cases and severe disease. They mark a milestone against one of history’s deadliest diseases.
A hard target
Malaria resists vaccines. The parasite is complex and evasive. Progress took decades.
Real protection
Trials delivered. Vaccines cut cases and severe illness. Lives could be saved.
Two vaccines
Options grew. A second, cheaper vaccine expanded supply. Access widened.
Rollout at scale
Delivery matters. Programs reached hundreds of thousands of children. Scale is real.
Partial efficacy
Caution applies. Protection is incomplete and wanes. Boosters are needed.
A layered fight
Context matters. Vaccines add to nets and drugs. The strategy is combined.
The bottom line
Malaria vaccines now reach children at scale, cutting cases and severe disease after decades of effort. A second, cheaper vaccine expanded supply. Protection is partial and complements existing tools.
